Shanghai Junshi Biosciences Co., Ltd.
Symbol: 1877.HK
HKSE
12.6
HKDMarket price today
-5.6777
P/E Ratio
0.0426
PEG Ratio
27.42B
MRK Cap
- 0.00%
DIV Yield
Shanghai Junshi Biosciences Co., Ltd. (1877-HK) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3778.1 | 5996.9 | 3504.6 | ||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 341.5 | ||||||||
balance-sheet.row.net-receivables | 0 | 483.2 | 517.7 | 1834.8 | ||||||||
balance-sheet.row.inventory | 0 | 538.1 | 599 | 484.6 | ||||||||
balance-sheet.row.other-current-assets | 0 | 744.4 | 91.3 | 7.7 | ||||||||
balance-sheet.row.total-current-assets | 0 | 5549.8 | 7204.9 | 5831.7 | ||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 4253.3 | 3572 | 3421.3 | ||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.intangible-assets | 0 | 134.4 | 110.5 | 51.8 | ||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 134.4 | 110.5 | 51.8 | ||||||||
balance-sheet.row.long-term-investments | 0 | 1133.1 | 1402.8 | 1123.4 | ||||||||
balance-sheet.row.tax-assets | 0 | 103.4 | 228.4 | 88.5 | ||||||||
balance-sheet.row.other-non-current-assets | 0 | 188.4 | 57.6 | 533.9 | ||||||||
balance-sheet.row.total-non-current-assets | 0 | 5812.6 | 5371.4 | 5219 | ||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-assets | 0 | 11362.5 | 12576.3 | 11050.7 | ||||||||
balance-sheet.row.account-payables | 0 | 247.3 | 281.6 | 196.2 | ||||||||
balance-sheet.row.short-term-debt | 0 | 575.3 | 435.4 | 45.1 | ||||||||
balance-sheet.row.tax-payables | 0 | 59.4 | 35.2 | 80.9 | ||||||||
balance-sheet.row.long-term-debt-total | 0 | 1213.2 | 886.2 | 583.1 | ||||||||
Deferred Revenue Non Current | 0 | 181.1 | 121.6 | 118.8 | ||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||
balance-sheet.row.other-current-liab | 0 | 7.5 | 1057.2 | 1775.4 | ||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1547.1 | 1007.8 | 701.9 | ||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.capital-lease-obligations | 0 | 53.4 | 90.2 | 127.6 | ||||||||
balance-sheet.row.total-liab | 0 | 4022.3 | 2782 | 2718.5 | ||||||||
balance-sheet.row.preferred-stock | 0 | 0.3 | 68.4 | 0 | ||||||||
balance-sheet.row.common-stock | 0 | 985.7 | 982.9 | 910.8 | ||||||||
balance-sheet.row.retained-earnings | 0 | -9040.8 | -6776.6 | -4388.6 | ||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -142.1 | -68.4 | 0.2 | ||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 15367.7 | 15295.2 | 11438.5 | ||||||||
balance-sheet.row.total-stockholders-equity | 0 | 7170.8 | 9501.4 | 7960.9 | ||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 11362.5 | 12576.3 | 11050.7 | ||||||||
balance-sheet.row.minority-interest | 0 | 169.4 | 292.8 | 371.3 | ||||||||
balance-sheet.row.total-equity | 0 | 7340.2 | 9794.3 | 8332.2 | ||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||
Total Investments | 0 | 1133.1 | 1402.8 | 1464.9 | ||||||||
balance-sheet.row.total-debt | 0 | 1788.6 | 1321.6 | 628.2 | ||||||||
balance-sheet.row.net-debt | 0 | -1989.6 | -4675.4 | -2876.4 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -2675.2 | -592.6 | -1669.5 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 293.7 | 262.6 | 151.4 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -173.8 | -5.7 | |||||||
cash-flows.row.stock-based-compensation | 0 | 91.9 | 192.8 | 30.7 | |||||||
cash-flows.row.change-in-working-capital | 0 | 687.2 | -318.8 | -13.1 | |||||||
cash-flows.row.account-receivables | 0 | 1229.7 | -770.6 | -482.2 | |||||||
cash-flows.row.inventory | 0 | -136.4 | -154.8 | -167 | |||||||
cash-flows.row.account-payables | 0 | -1229.7 | 770.6 | 482.2 | |||||||
cash-flows.row.other-working-capital | 0 | 823.6 | -163.9 | 153.9 | |||||||
cash-flows.row.other-non-cash-items | 0 | -172.9 | -12 | 7.3 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -394 | -886.2 | -592.7 | |||||||
cash-flows.row.acquisitions-net | 0 | -93.8 | -440.1 | 2.9 | |||||||
cash-flows.row.purchases-of-investments | 0 | -8.5 | -1169.6 | -245.2 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 565.3 | 70.1 | |||||||
cash-flows.row.other-investing-activites | 0 | 28.6 | 49.7 | 66.8 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -467.6 | -1881 | -698 | |||||||
cash-flows.row.debt-repayment | 0 | -113.4 | -793.3 | -401.4 | |||||||
cash-flows.row.common-stock-issued | 0 | 3812.3 | 2150.1 | 4846.9 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 19.2 | 16.7 | 43.2 | |||||||
cash-flows.row.dividends-paid | 0 | -19.2 | -16.7 | -43.2 | |||||||
cash-flows.row.other-financing-activites | 0 | 944.2 | 1308.9 | -32 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 4643 | 2665.7 | 4413.5 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 92.3 | -23.2 | -45.8 | |||||||
cash-flows.row.net-change-in-cash | 0 | 2492.3 | 119.6 | 2171 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 5996.9 | 3504.6 | 3385 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3504.6 | 3385 | 1214 | |||||||
cash-flows.row.operating-cash-flow | 0 | -1775.3 | -641.9 | -1498.8 | |||||||
cash-flows.row.capital-expenditure | 0 | -394 | -886.2 | -592.7 | |||||||
cash-flows.row.free-cash-flow | 0 | -2169.3 | -1528.1 | -2091.5 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1502.5 | 1453.5 | 4024.8 | ||||||||
income-statement-row.row.cost-of-revenue | 0 | 667.3 | 526.3 | 1258.2 | ||||||||
income-statement-row.row.gross-profit | 0 | 835.3 | 927.2 | 2766.7 | ||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.other-expenses | 0 | -35.8 | -34.2 | -91.9 | ||||||||
income-statement-row.row.operating-expenses | 0 | 3287.3 | 3644.2 | 3359.4 | ||||||||
income-statement-row.row.cost-and-expenses | 0 | 3954.6 | 4170.4 | 4617.5 | ||||||||
income-statement-row.row.interest-income | 0 | 99.4 | 61 | 31 | ||||||||
income-statement-row.row.interest-expense | 0 | 29 | 29.4 | 21.8 | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -15.7 | -3.6 | 92.7 | ||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||
income-statement-row.row.other-operating-expenses | 0 | -35.8 | -34.2 | -91.9 | ||||||||
income-statement-row.row.total-operating-expenses | 0 | -15.7 | -3.6 | 92.7 | ||||||||
income-statement-row.row.interest-expense | 0 | 29 | 29.4 | 21.8 | ||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 303.2 | 293.7 | 262.6 | ||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||
income-statement-row.row.operating-income | 0 | -2476 | -2671.6 | -685.3 | ||||||||
income-statement-row.row.income-before-tax | 0 | -2489.9 | -2675.2 | -592.6 | ||||||||
income-statement-row.row.income-tax-expense | 0 | 44 | -93.1 | 135.5 | ||||||||
income-statement-row.row.net-income | 0 | -2281.6 | -2582.1 | -728.2 |
Frequently Asked Question
What is Shanghai Junshi Biosciences Co., Ltd. (1877.HK) total assets?
Shanghai Junshi Biosciences Co., Ltd. (1877.HK) total assets is 11362464000.000.
What is enterprise annual revenue?
The annual revenue is N/A.
What is firm profit margin?
Firm profit margin is -0.024.
What is company free cash flow?
The free cash flow is -2.642.
What is enterprise net profit margin?
The net profit margin is -3.152.
What is firm total revenue?
The total revenue is -3.231.
What is Shanghai Junshi Biosciences Co., Ltd. (1877.HK) net profit (net income)?
The net profit (net income) is -2281624000.000.
What is firm total debt?
The total debt is 1788567000.000.
What is operating expences number?
The operating expences are 3287276000.000.
What is company cash figure?
Enretprise cash is 0.000.